Skye Bioscience (SKYE) Other Non Operating Income (2016 - 2026)
Skye Bioscience (SKYE) posted quarterly Other Non Operating Income of -$2411.0 for Q1 2026, down 105.93% year-over-year from $40641.0 in Q1 2025, and down 380.28% quarter-over-quarter from -$502.0 in Q4 2025.
Skye Bioscience (SKYE) Other Non Operating Income (2016 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported Other Non Operating Income for 11 consecutive years, with -$2411.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income fell 105.93% year-over-year to -$2411.0; the TTM figure through Mar 2026 stood at -$2913.0 (down 107.38% YoY), while the FY2025 annual figure was -$502.0, up 77.18% from the prior year.
- Other Non Operating Income slipped to -$2411.0 in Q1 2026 per SKYE's latest filing, from -$502.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $40641.0 in Q1 2025 and bottomed at -$43655.0 in Q1 2022.
- Historically, Other Non Operating Income has averaged -$2200.4 across 5 years, with a median of -$801.0 in 2024.
- Annual changes were most pronounced in 2024 — Other Non Operating Income tumbled 34566.67% — and 2025, when it surged 4007.79%.
- Skye Bioscience's Other Non Operating Income stood at -$323.0 in 2022, then jumped by 99.07% to -$3.0 in 2023, then plunged by 26600.0% to -$801.0 in 2024, then soared by 37.33% to -$502.0 in 2025, then tumbled by 380.28% to -$2411.0 in 2026.
- Business Quant data shows SKYE's Other Non Operating Income at -$2411.0 in Q1 2026, -$502.0 in Q4 2025, and $40641.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Skye Bioscience | 10.86 Mn | 10.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,411.00 |
| Dec 31, 2025 | -502.00 |
| Mar 31, 2025 | 40,641.00 |
| Sep 30, 2024 | -801.00 |
| Jun 30, 2024 | -359.00 |
| Mar 31, 2024 | -1,040.00 |
| Mar 31, 2023 | -3.00 |
| Dec 31, 2022 | -323.00 |
| Sep 30, 2022 | -6,228.00 |
| Jun 30, 2022 | -9,523.00 |
| Mar 31, 2022 | -43,655.00 |
| Dec 31, 2021 | -148,184.00 |
| Sep 30, 2021 | -189,649.00 |
| Jun 30, 2021 | 117,953.00 |
| Mar 31, 2021 | 238,350.00 |
| Jun 30, 2020 | 26,353.00 |
| Mar 31, 2020 | -35,903.00 |
| Dec 31, 2019 | 4.04 Mn |
| Sep 30, 2019 | 3.13 Mn |
| Jun 30, 2019 | -17.97 Mn |